The aim of the present study was to assess the prevalence of the IDH1105GGT SNP in a cohort of Italian patients with brain tumors classified according to 2016 WHO criteria, and investigate its association with clinicopathologic features and IDH tumor missense mutations. Here, IDH2 is linked to brain neoplasm.